EXEL — Exelixis Inc · P/E 17, rev $628.7M

Exelixis Inc (EXEL) is a biotechnology company listed on US.

Latest reported EXEL revenue for 2026-07-03 was $628.7M. Net income was $212.1M. Revenue was up 2.9% from 2026-04-03 to 2026-07-03. EXEL currently screens at market cap $12.69B and trailing P/E 16.7.

Use this EXEL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the EXEL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the EXEL SEC filings page. Lician reads the product cache first so this HTML stays unique to Exelixis Inc even when a live quote feed is slow.

Exelixis Inc latest statements (FY2026)

Latest cached year on this hub. Full EXEL income, balance, and cash tables.

  • Revenue$2.32B
  • Net Income$782.6M
  • Total Assets$2.84B
  • Total Debt$0
  • Free Cash Flow$892.7M

EXEL recent filings